Transapical Mitral Valve Replacement: 1-Year Results of the Real-World Tendyne European Experience Registry.
Gutenberg Open Science · 2024-01-01
DOI: 10.25358/openscience-12863 ↗At a glance
Journal article in Gutenberg Open Science, published on 2024-01-01. Written by Hell and 39 co-authors. Cited 2 times so far (Crossref).
Abstract (original language)
BACKGROUND Early studies of the Tendyne transcatheter mitral valve replacement (TMVR) showed promising results in a small selective cohort. OBJECTIVES The authors present 1-year data from the currently largest commercial, real-world cohort originating from the investigator-initiated TENDER (Tendyne European Experience) registry. METHODS All patients from the TENDER registry eligible for 1-year follow-up were included. The primary safety endpoint was 1-year cardiovascular mortality. Primary performance endpoint was reduction of mitral regurgitation (MR) up to 1 year. RESULTS Among 195 eligible patients undergoing TMVR (median age 77 years [Q1-Q3: 71-81 years], 60% men, median Society of Thoracic Surgeons Predicted Risk of Mortality 5.6% [Q1-Q3: 3.6%-8.9%], 81% in NYHA functional class III or IV, 94% with MR 3+/4+), 31% had "real-world" indications for TMVR (severe mitral annular calcification, prior mitral valve treatment, or others) outside of the instructions for use. The technical success rate was 95%. The cardiovascular mortality rate was 7% at 30 day and 17% at 1 year (all-cause mortality rates were 9% and 29%, respectively). Reintervention or surgery following discharge was 4%, while rates of heart failure hospitalization reduced from 68% in the preceding year to 25% during 1-year follow-up. Durable MR reduction to ≤1+ was achieved in 98% of patients, and at 1 year, 83% were in NYHA functional class I or II. There was no difference in survival and major adverse events between on-label use and "real-world" indications up to 1 year. CONCLUSIONS This large, real-world, observational registry reports high technical success, durable and complete MR elimination, significant clinical benefits, and a 1-year cardiovascular mortality rate of 17% after Tendyne TMVR. Outcomes were comparable between on-label use and "real-world" indications, offering a safe and efficacious treatment option for patients without alternative treatments. (Tendyne European Experience Registry [TENDER]; NCT04898335).
Subjects
Cite
APA
Hell, M., M., Wild, M. G., Baldus, Stephan, Rudolph, T. K., Treede, Hendrik, Petronio, A. S., Modine, T., Andreas, Martin, Coisne, A., Duncan, Alison, Franco, Nombela, L., Praz, F., Ruge, H., …, & Investigators, T. (2024). Transapical Mitral Valve Replacement: 1-Year Results of the Real-World Tendyne European Experience Registry. Gutenberg Open Science. https://doi.org/10.25358/openscience-12863
Vancouver
Hell, M. M, Wild MG, Baldus, Stephan, Rudolph TK, et al. Transapical Mitral Valve Replacement: 1-Year Results of the Real-World Tendyne European Experience Registry. Gutenberg Open Science. 2024. doi:10.25358/openscience-12863
BibTeX
@article{Hell2024,
author = {Hell and M., Michaela and Wild, Mirjam Gauri and Baldus and Stephan and Rudolph, Tanja K. and Treede and Hendrik and Petronio, Anna Sonia and Modine, Thomas and Andreas and Martin and Coisne, Augustin and Duncan and Alison and Franco and Nombela, Luis and Praz, Fabien and Ruge, Hendrik and Conradi and Lenard and Zierer, Andreas F. and Anselmi, Amédéo and Dumonteil, Nicolas and Nickenig, Georg and Piñón and Miguel and Barth, Sebastian and Adamo and Marianna and Dubois, Christophe and Torracca and Lucia and Maisano and Francesco and Lurz, Philipp C. and Bardeleben, Ralph Stefan von and Hausleiter and Jörg and Investigators, TENDER},
title = {Transapical Mitral Valve Replacement: 1-Year Results of the Real-World Tendyne European Experience Registry},
journal = {Gutenberg Open Science},
year = {2024},
doi = {10.25358/openscience-12863}
}
EUVIMED